Triumph's Recap of CBI's Risk-Based Monitoring 2013
Validation - a word we use a lot in this industry. For Triumph Consultancy Services, it is usually a term which we associate with systems development, but on this occasion I'm excited to say I'm talking about validation of our new business division and its ideas.
SPOTLIGHT EVENT
Cambridge, MassachusettsDownload Brochure
RELATED
-
- Risk-Based Approaches
- ICON Exec Discusses ICONIK MonitoringMore in Risk-Based Monitoring
Validation - a word we use a lot in this industry. For Triumph Consultancy Services, it is usually a term which we associate with systems development, but on this occasion I'm excited to say I'm talking about validation of our new business division and its ideas. This week I was privileged to present at the CBI's Risk-Based Monitoring event in Philadelphia. For the first time since its incorporation, I was presenting as the CEO of Triumph Research Intelligence - a division of Triumph set up with the specific purpose of bringing the best possible Risk-Based Monitoring approach, software platform and services to the life sciences industry.
Having just released our
2013 has been a year of RBM information gathering for the industry and it looks like 2014 is going to be a year of action, learning and further development. There is anticipation and excitement abounding right now, and I think we all realise that RBM is a genuine opportunity to solve some of the quality and cost challenges that are so prevalent in the industry today. Triumph Research Intelligence are well positioned to support the industry on that journey and will continue to invest heavily in our software platform and supporting services to ensure we can support our clients and the industry as a whole to the best of our abilities.
So what did validation mean for us this week? A queue of people waiting for me as I left the podium that day, and beyond that, a further queue of people waiting to talk to us at our exhibition stand. Validation - it feels good to use the term in such a positive light!
Triumph's RBM position paper can be downloaded at
Duncan Hall can be contacted at
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025